摘要
目的:深入探讨乌司他丁联合生长抑素对重症急性胰腺炎(SAP)患者的临床疗效。方法:选取2021年3月至2023年7月期间本院收治的86例SAP患者,随机分为两组,每组43例。对照组采用生长抑素治疗,研究组则在此基础上联合乌司他丁治疗,均持续7d。通过对比分析两组的临床效果、症状缓解时间、炎症因子(TNF-α、IL-6、CRP)及胰功能指标的变化,并监测不良反应(如肝功肾功能异常、肠麻痹、休克)发生率。结果:研究组总有效率达93.02%,显著高于对照组(76.74%,P<0.05);研究组在症状缓解及胰淀粉酶恢复时间上均显著优于对照组(P<0.05);炎症因子及胰功能指标改善更为显著(P<0.05);且研究组并发症发生率更低(9.30%vs 18.60%,P<0.05)。结论:乌司他丁联合生长抑素治疗SAP疗效、康复速度更优,并发症风险较低,可为SAP的临床治疗方案优化提供思路。
Objective:To comprehensively investigate the clinical efficacy of ulinastatin combined with somatostatin in the treatment of patients with severe acute pancreatitis(SAP).Methods:A total of 86 SAP patients admitted to our hospital from March 2021 to July 2023 were randomly divided into two groups,with 43 patients in each group.The control group received somatostatin treatment,while the study group received a combination therapy of somatostatin and ulinastatin for 7 consecutive days.The clinical outcomes,symptom relief time,changes in inflammatory factors(TNF-α,IL-6,CRP),and pancreatic function indicators were compared and analyzed between the two groups.Additionally,the incidence of adverse reactions(such as abnormal liver and kidney function,intestinal paralysis,and shock)was monitored.Results:The total effective rate in the study group reached 93.02%,significantly higher than that in the control group(76.74%,P<0.05).The study group also demonstrated significantly better outcomes in symptom relief and pancreatic amylase recovery time compared to the control group(P<0.05).Moreover,the improvement in inflammatory factors and pancreatic function indicators was more pronounced in the study group(P<0.05).Furthermore,the incidence of complications in the study group was lower(9.30%vs 18.60%,P<0.05).Conclusion:The combination therapy of ulinastatin and somatostatin for SAP exhibits higher efficacy,faster recovery,and a lower risk of complications,providing an optimized treatment option for clinical management of SAP.
作者
周涛
孙超艳
闫登峰
ZHOU Tao;SUN Chao-yan;YAN Deng-feng(Zhoukou Central Hospital,Henan Zhoukou 464400,China)
出处
《中国药物评价》
2024年第5期414-418,共5页
Chinese Journal of Drug Evaluation
